Sanofi
Sanofi’s ‘Play to Win’ strategy backfires, stock tumbles
Sanofi is facing investor discontent as its CEO, Paul Hudson, unveiled the latest chapter in the “Play to Win” strategy ...
Sanofi suffers setbacks for three acquired assets in clinical trials
Sanofi has faced challenges with a trio of therapeutic candidates acquired through its business development endeavors, leading to a pause ...
RSV outbreak causes shortage of Sanofi, AZ’s Beyfortus
Shortly after Sanofi and AstraZeneca secured a significant FDA approval for their respiratory syncytial virus (RSV) antibody, Beyfortus, the highly ...
Dupixent Fails to Win FDA Approval for Hives Disorder, Needs More Data
Regeneron and Sanofi have faced an unexpected hurdle in their pursuit of regulatory approval for Dupixent, a monoclonal antibody aimed ...
Sanofi launches soccer program for homeless people in Korea with ‘Dream’ team
Sanofi’s South Korea branch organized an indoor soccer game known as futsal to address the social isolation experienced by homeless ...
Astria buys rights to Ichnos’ eczema drug for $15M, joining crowded field of Amgen and Sanofi
Ichnos Sciences has secured a buyer for its OX40 eczema program, with Astria Therapeutics entering the scene by paying an ...
Sanofi partners with Ipsos to understand hemophilia patients’ needs and challenges
Sanofi’s extensive exploration into the world of hemophilia patients, caregivers, and healthcare providers has yielded valuable insights. Collaborating with The ...
Sanofi invests $10M in Proteome Sciences to access its protein map for drug discovery
Sanofi has taken a significant step toward its goal of becoming the first pharmaceutical company to harness the power of ...
EuroAPI lowers sales forecast due to CDMO challenges and inventory cuts by customers
The Contract Development and Manufacturing Organization (CDMO) sector, which experienced a surge in business during the COVID-19 pandemic, is grappling ...
Sanofi Considers Acquisition of Mirati Amid Intensifying KRAS Cancer Drug Battle, Reports Bloomberg
Mirati Therapeutics experienced a significant surge in its stock price on Thursday, triggered by swirling rumors of a potential acquisition ...
Sanofi Joins Forces with Teva, Merck, and Roivant in $500M Deal for Bowel Disease Race
Sanofi is making significant financial moves in the pharmaceutical landscape. Just one day after sealing a $175 million vaccine deal, ...
Sanofi Invests $175M in J&J’s Advanced E. coli Vaccine, Amplifying its Vaccine Development Efforts
Sanofi is making a strategic move by investing $175 million in Johnson & Johnson’s late-phase E. coli vaccine, ExPEC9V. As ...
Pharmanovia buys 11 CNS drugs from Sanofi to expand its portfolio of repurposed medicines
Sanofi, in its ongoing effort to streamline its product portfolio, is divesting 11 central nervous system (CNS) medications to Pharmanovia, ...
Johnson & Johnson rebrands itself with a new logo and slogan
First Sanofi, GSK, and now Johnson & Johnson are all undergoing significant rebranding efforts in the pharmaceutical industry. In a ...
First Wave acquires Sanofi’s Alzheimer’s drug for GI disorders, retains buyback option
First Wave BioPharma has seized an opportunity from Sanofi to revive a long-dormant molecule, capeserod, by paying an upfront sum ...
Sanofi teams up with Ice-T to scare people into getting flu shots
Sanofi is breaking the mold with a bold and captivating campaign aimed at alerting older adults to the perils of ...
Sanofi’s specialty care chief Sibold leaves amid executive reshuffle
After an impressive six-year tenure steering Sanofi’s specialty care division, Bill Sibold is bidding adieu to embrace a new external ...
GSK’s Arexvy Takes Lead in RSV Vaccine Race, Now Accessible at Leading US Pharmacies
In the competitive landscape of the respiratory syncytial virus (RSV) vaccine market, GlaxoSmithKline (GSK) stands out with its well-timed strides. ...
Sanofi Fails to Secure Reata in Bidding Battle Against Biogen Following Horizon Setback
Biogen’s pursuit of Reata, a rare disease company based in Texas, has unveiled a compelling narrative of corporate rivalry and ...
Beyfortus: A Breakthrough RSV Shot for Infants Approved by CDC
Source – Sanofi The US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has given ...
Qunol, a rapidly expanding US brand in the healthy aging market, will be acquired by Sanofi
Source – Sanofi Paris, July 28, 2023. Sanofi announces its strategic move to acquire Qunol, a renowned and leading brand ...
Sanofi Reports ‘Solid’ Q2 Performance with 3 Ongoing Launches and Dupixent Nearing €10B Milestone
Sanofi, a leading pharmaceutical company, is navigating the challenges posed by the entry of generic versions of its drug Aubagio ...
The UK is looking into GLP-1 medications made by Novo Nordisk, AstraZeneca, Lilly, and Sanofi for GLP-1 inhibitor suicide risk
Following the European Union’s lead, the United Kingdom has initiated an investigation into the potential suicide risks associated with popular ...
FDA has approved Beyfortus as a treatment for RSV illness in newborns
Source – Sanofi On July 17, 2023 Sanofi and AstraZeneca received approval from the US Food and Drug Administration (FDA) ...
Sanofi teams up with local pharma firms for vaccine production in Saudi Arabia
Following recent developments by AstraZeneca and National Resilience in the United Arab Emirates, Sanofi has emerged as the next major ...
The pipeline for RSV, influenza, meningitis, and pneumococcal disease vaccines raises the bar
Source – Sanofi On June 29, 2023, Sanofi is hosting an investor event focused on its Vaccines pipeline, featuring key ...
A recent study demonstrates the efficacy of the digital Dario tool in managing severe diabetes
Source – DarioHealth A joint effort between DarioHealth and Sanofi has yielded promising results in a real-world study presented at ...
Promising Phase IIb Results in Atopic Dermatitis: amlitelimab as a Groundbreaking Treatment
Source – Sanofi On June 27, 2023, Sanofi announced positive Phase IIb Results. Amlitelimab shows promise as a first-in-class investigational ...
Altuviiio a weekly Administration Provides Effective Bleed Prevention for Severe Hemophilia A in Children
Source – Sanofi On June 26, 2023, at the Annual Meeting of the International Society on Thrombosis and Haemostasis (ISTH) ...
Boehringer Ingelheim’s Zantac arbitration is won by Sanofi
Source – Sanofi On 20 June 2023 in Paris, Sanofi reports that the International Chamber of Commerce tribunal has rejected ...
